Tenecteplase: A review

Clinical Therapeutics

Volumn 23, Issue 7, 2001, Pages 982-997

  Davydov, Liya ^a   Cheng, Judy W M ^a,b  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b LONG ISLAND UNIVERSITY   (United States)

Author keywords

Acute myocardial infarction; Clinical pharmacology; Tenecteplase; Thrombolytic

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; BLOOD CLOT LYSIS; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; NONHUMAN; REVIEW;

EID: 0034905963     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(01)80086-2     Document Type: Article

References (45)

1. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
2. Prevention of myocardial damage in acute myocardial ischemia by early treatment with intravenous streptokinase
3. Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial
4. Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction?
5. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction
6. TNK-tPA for acute myocardial infarction: The clinical experience
7. The ideal fibrinolytic: Can drug design improve clinical results?
8. A comparison of reteplase with alteplase for acute myocardial infarction
9. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction
10. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): Trial to investigate equivalence
11. A faster-acting and more potent form of tissue plasminogen activator
12. Pharmacological and clinical impact of the unique molecular structure of a new plasminogen activator
13. Molecular biology of plasminogen activators: What are the clinical implications of drug design?
14. Tenecteplase (TNKase) for thrombolysis
15. Identification of the mechanism responsible for the increased fibrin specificity of TNK-tissue plasminogen activator relative to tissue plasminogen activator
16. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA
17. Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction
18. A pilot study of the efficacy and safety of bolus administration of alteplase in acute myocardial infarction
19. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial
20. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction. Results of the TIMI 10B trial
21. Pharmacokinetics and pharmacodynamics of tenecteplase: Results from a phase II study in patients with acute myocardial infarction
22. Concurrent nitroglycerin therapy impairs tissue-type plasminogen activator-induced thrombolysis in patients with acute myocardial infarction
23. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: Comparison of nine plasminogen activators in vitro
24. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog
25. A slow clearing, fibrin-specific, PAI-1 resistant variant of tPA (T103N, KHRR 296-299 AAAA)
26. A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding
27. A variant of tissue plasminogen activator (T103N, N117Q, KHRR296-299AAAA) with a decreased plasma clearance rate, is substantially more potent than Activase rtPA in a rabbit thrombolysis model
28. Real-time measurement of lysis of mural platelet deposits by fibrinolytic agents under arterial flow
29. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings
30. TIMI frame count: A quantitative method of assessing coronary artery flow
31. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase, and combination thrombolytic therapy for acute myocardial infraction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial
32. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) phase II trial
33. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial
34. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial
35. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: The ASSENT-1 trial
36. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial
37. Comparison of clinical signs and hemodynamic state in the early hours of transmural myocardial infarction
38. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI), phase II trial
39. Thrombolysis in Myocardial Infarction (TIMI): Comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator
40. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction
41. Safety and efficacy of 50 milligrams of tenecteplase in patients with acute myocardial infarction: Results from ASSENT-2
42. The GUSTO trial and the open artery theory